Structure Activity Relationships of α-L-LNA Modified Phosphorothioate Gapmer Antisense Oligonucleotides in Animals
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
We report the structure activity relationships of short 14-mer phosphorothioate gapmer antisense oligonucleotides (ASOs) modified with α-L-locked nucleic acid (LNA) and related modifications targeting phosphatase and tensin homologue (PTEN) messenger RNA in mice. α-L-LNA represents the α-anomer of enantio-LNA and modified oligonucleotides show LNA like binding affinity for complementary RNA. In contrast to sequence matched LNA gapmer ASOs which showed elevations in plasma alanine aminotransferase (ALT) levels indicative of hepatotoxicity, gapmer ASOs modified with α-L-LNA and related analogs in the flanks showed potent downregulation of PTEN messenger RNA in liver tissue without producing elevations in plasma ALT levels. However, the α-L-LNA ASO showed a moderate dose-dependent increase in liver and spleen weights suggesting a higher propensity for immune stimulation. Interestingly, replacing α-L-LNA nucleotides in the 3'- and 5'-flanks with R-5'-Me-α-L-LNA but not R-6'-Me- or 3'-Me-α-L-LNA nucleotides, reversed the drug induced increase in organ weights. Examination of structural models of dinucleotide units suggested that the 5'-Me group increases steric bulk in close proximity to the phosphorothioate backbone or produces subtle changes in the backbone conformation which could interfere with recognition of the ASO by putative immune receptors. Our data suggests that introducing steric bulk at the 5'-position of the sugar-phosphate backbone could be a general strategy to mitigate the immunostimulatory profile of oligonucleotide drugs. In a clinical setting, proinflammatory effects manifest themselves as injection site reactions and flu-like symptoms. Thus, a mitigation of these effects could increase patient comfort and compliance when treated with ASOs.Molecular Therapy - Nucleic Acids (2012) 1, e47; doi:10.1038/mtna.2012.34; published online 18 September 2012.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LNA-mediated microRNA silencing in non-human primates
Elmén, J., Lindow, M., Schütz, S., Lawrence, M., Petri, A., Obad, S., Lindholm, M., Hedtjärn, M., Hansen, H. F., Berger, U., et al. (2008) · Nature · doi:10.1038/nature06783 · Cited by 1,589
Research works printed but not linked: 38
- Bennett, 2010, RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform, Annu Rev Pharmacol Toxicol, 50, 259, 10.1146/annurev.pharmtox.010909.105654 · DOI · Paper page
- Altmann, 1997, Second generation antisense oligonucleotides – inhibition of pkc-alpha and c-raf kinase expression by chimeric oligonucleotides incorporating 6’-substituted carbocyclic nucleosides and 2’-O-ethylene glycol substituted ribonucleosides, Nucleosides, Nucleotides and Nucleic Acids, 16, 917, 10.1080/07328319708006108 · doi:10.1080/07328319708006108
- Raal, 2010, Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial, Lancet, 375, 998, 10.1016/S0140-6736(10)60284-X · DOI · Paper page
- Swayze, 2007, Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals, Nucleic Acids Res, 35, 687, 10.1093/nar/gkl1071 · DOI · Paper page
- Seth, 2009, Short antisense oligonucleotides with novel 2′-4′ conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals, J Med Chem, 52, 10, 10.1021/jm801294h · DOI · Paper page
- Seth, 2010, Synthesis and biophysical evaluation of 2′,4′-constrained 2′O-methoxyethyl and 2′,4′-constrained 2′O-ethyl nucleic acid analogues, J Org Chem, 75, 1569, 10.1021/jo902560f · DOI · Paper page
- Seth, 2010, Configuration of the 5′-Methyl Group Modulates the Biophysical and Biological Properties of Locked Nucleic Acid (LNA), Oligonucleotides J Med Chem, 53, 8309
- Seth, 2010, An exocyclic methylene group acts as a bioisostere of the 2′-oxygen atom in LNA, J Am Chem Soc, 132, 14942, 10.1021/ja105875e · DOI
- Zhou, 2012, Intramolecular Free-Radical Cyclization Reactions on Pentose Sugars for the Synthesis of Carba-LNA and Carba-ENA and the Application of Their Modified Oligonucleotides as Potential RNA Targeted Therapeutics, Chem Rev, 112, 3808, 10.1021/cr100306q · DOI
- Rajwanshi, 2000, Angew Chem Int Ed Engl, 39, 1656, 10.1002/(SICI)1521-3773(20000502)39:9<1656::AID-ANIE1656>3.0.CO;2-Q · DOI
- Sørensen, 2002, α-L-ribo-configured locked nucleic acid (α-L-LNA): synthesis and properties, J Am Chem Soc, 124, 2164, 10.1021/ja0168763 · DOI
- Petersen, 2001, α-L-LNA (α-L-ribo configured locked nucleic acid) recognition of RNA. A study by NMR spectroscopy and molecular dynamics simulations, J Am Chem Soc, 123, 7431, 10.1021/ja010557u · DOI
- Nielsen, 2002, α-L-LNA (α-L-ribo configured locked nucleic acid) recognition of DNA: an NMR spectroscopic study, Chemistry, 8, 3001, 10.1002/1521-3765(20020703)8:13<3001::AID-CHEM3001>3.0.CO;2-1 · doi:10.1002/1521-3765(20020703)8:13<3001::aid-chem3001>3.0.co;2-1
- Nielsen, 2003, NMR structure of an α-L-LNA:RNA hybrid: structural implications for RNase H recognition, Nucleic Acids Res, 31, 5858, 10.1093/nar/gkg800 · DOI
- Bondensgaard, 2000, Structural studies of LNA:RNA duplexes by NMR: conformations and implications for RNase H activity, Chemistry, 6, 2687, 10.1002/1521-3765(20000804)6:15<2687::AID-CHEM2687>3.0.CO;2-U · DOI
- Fluiter, 2005, On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide, Chembiochem, 6, 1104, 10.1002/cbic.200400419 · doi:10.1002/cbic.200400419
- Murray, 2012, TricycloDNA-modified oligo-2’-deoxyribonucleotides reduce scavenger receptor B1 mRNA in hepatic and extra-hepatic tissues–a comparative study of oligonucleotide length, design and chemistry, Nucleic Acids Res, 10.1093/nar/gks273 · DOI · Paper page
- Straarup, 2010, Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates, Nucleic Acids Res, 38, 7100, 10.1093/nar/gkq457 · DOI · Paper page
- Kumar, 2007, 2′-N-(pyren-1-yl)acetyl-2′-amino-α-L-LNA: synthesis and detection of single nucleotide mismatches in DNA and RNA targets, Chembiochem, 8, 1122, 10.1002/cbic.200700144 · doi:10.1002/cbic.200700144
- Kumar, 2008, Nucleic acid structural engineering using pyrene-functionalized 2′-amino-α-L-LNA monomers and abasic sites, J Org Chem, 73, 7060, 10.1021/jo800551j · DOI
- Kumar, 2009, Functionalized 2′-amino-α-L-LNA: directed positioning of intercalators for DNA targeting, J Org Chem, 74, 1070, 10.1021/jo802037v · doi:10.1021/jo802037v
- Li, 2010, Free-radical ring closure to conformationally locked α-L-carba-LNAs and synthesis of their oligos: nuclease stability, target RNA specificity, and elicitation of RNase H, J Org Chem, 75, 6122, 10.1021/jo100900v · doi:10.1021/jo100900v
- Seth, 2011, Replacing the 2′-oxygen with an exocyclic methylene group reverses the stabilization effects of α-L-LNA, Bioorg Med Chem Lett, 21, 588, 10.1016/j.bmcl.2010.10.025 · DOI
- Seth, 2011, Synthesis and biophysical characterization of R-6′-Me-α-L-LNA modified oligonucleotides, Bioorg Med Chem Lett, 21, 1122, 10.1016/j.bmcl.2010.12.119 · doi:10.1016/j.bmcl.2010.12.119
- Seth, 2012, Structural requirements for hybridization at the 5′-position are different in α-L-LNA as compared to β-D-LNA, Bioorg Med Chem Lett, 22, 296, 10.1016/j.bmcl.2011.11.012 · doi:10.1016/j.bmcl.2011.11.012
- Seth, 2011, Synthesis and biophysical evaluation of 3′-Me-α-L-LNA – Substitution in the minor groove of α-L-LNA duplexes, Bioorg Med Chem Lett, 21, 4690, 10.1016/j.bmcl.2011.06.104 · DOI
- Prakash, 2010, Antisense oligonucleotides containing conformationally constrained 2′,4′-(N-methoxy)aminomethylene and 2′,4′-aminooxymethylene and 2′-O,4′-C-aminomethylene bridged nucleoside analogues show improved potency in animal models, J Med Chem, 53, 1636, 10.1021/jm9013295 · doi:10.1021/jm9013295
- Egli, 2011, Synthesis, improved antisense activity and structural rationale for the divergent RNA affinities of 3′-fluoro hexitol nucleic acid (FHNA and Ara-FHNA) modified oligonucleotides, J Am Chem Soc, 133, 16642, 10.1021/ja207086x · DOI
- Freier, 1997, The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes, Nucleic Acids Res, 25, 4429, 10.1093/nar/25.22.4429 · DOI · Paper page
- Henry, 2000, Chemically modified oligonucleotides exhibit decreased immune stimulation in mice, J Pharmacol Exp Ther, 292, 468, 10.1016/S0022-3565(24)35315-7 · DOI · Paper page
- Petersen, 2002, Locked nucleic acid (LNA) recognition of RNA: NMR solution structures of LNA:RNA hybrids, J Am Chem Soc, 124, 5974, 10.1021/ja012288d · DOI · Paper page
- Rosenberg, 1976, RNA double helices generated from crystal structures of double helical dinucleoside phosphates, Biochem Biophys Res Commun, 69, 979, 10.1016/0006-291X(76)90469-1 · DOI
- Egli, 1996, Structural aspects of nucleic acid analogs and antisense oligonucleotides, Angew Chem Int Ed, 35, 1894, 10.1002/anie.199618941 · DOI
- Pallan, 2012, Structure and nuclease resistance of 2′,4′-constrained 2′-O-methoxyethyl (cMOE) and 2′-O-ethyl (cEt) modified DNAs, Chem Commun (Camb), 48, 8195, 10.1039/c2cc32286b · DOI
- Meldgaard, 2004, 3′-C-Branched LNA-type nucleosides locked in an N-type furanose ring conformation: synthesis, incorporation into oligodeoxynucleotides, and hybridization studies, J Org Chem, 69, 6310, 10.1021/jo049159a · doi:10.1021/jo049159a
- Pallan, 2012, Insights from crystal structures into the opposite effects on RNA affinity caused by the S- and R-6′-methyl backbone modifications of 3′-fluoro hexitol nucleic acid, Biochemistry, 51, 7, 10.1021/bi201810r · doi:10.1021/bi201810r
- Yanai, 2011, Suppression of immune responses by nonimmunogenic oligodeoxynucleotides with high affinity for high-mobility group box proteins (HMGBs), Proc Natl Acad Sci USA, 108, 11542, 10.1073/pnas.1108535108 · DOI · Paper page
- Lanford, 2010, Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection, Science, 327, 198, 10.1126/science.1178178 · DOI · Paper page
Cited by
The Medicinal Chemistry of Therapeutic Oligonucleotides
Wan, W. B., & Seth, P. P. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00551 · Cited by 429
Self-citationPharmacology of Antisense Drugs
Bennett, C. F., Baker, B. F., Pham, N., Swayze, E., & Geary, R. S. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104846 · Cited by 425
Self-citationMirror‐Image Oligonucleotides: History and Emerging Applications
Young, B. E., Kundu, N., & Sczepanski, J. T. (2019) · Chemistry – A European Journal · doi:10.1002/chem.201900149 · Cited by 93
Sewing, S., Roth, A. B., Winter, M., Dieckmann, A., Bertinetti-Lapatki, C., Tessier, Y., McGinnis, C., Huber, S., Koller, E., Ploix, C., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0187574 · Cited by 52
Injection site reactions after subcutaneous oligonucleotide therapy
van Meer, L., Moerland, M., Gallagher, J., van Doorn, M. B. A., Prens, E. P., Cohen, A. F., Rissmann, R., & Burggraaf, J. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12961 · Cited by 45
Metadata
- Authors
- Seth, P. P., Jazayeri, A., Yu, J., Allerson, C. R., Bhat, B., & Swayze, E. E.
- Venue
- Molecular Therapy - Nucleic Acids
- Publisher
- Elsevier BV
- Published
- 2012
- Volume
- 1
- Pages
- e47
- ISSN
- 2162-2531 (ISSN-L)
- OpenAlex
- W2046827424
- Cited by
- 44
- References
- 1
- FWCI
- 1.63
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/3.0/ (vor, 1741 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.